Menu Search
Equities

Antibe Therapeutics Inc(Pre-Merger)

ATBPF:PKC

Antibe Therapeutics Inc(Pre-Merger)

Actions
  • Price (USD)0.2156
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-41.78%
  • Beta--
Data delayed at least 15 minutes, as of May 20 2024 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-18.24m
  • Incorporated2009
  • Employees11.00
  • Location
    Antibe Therapeutics Inc(Pre-Merger)15 Prince Arthur AvenueTORONTO M5R 1B2CanadaCAN
  • Phone+1 (905) 726-0995
  • Fax+1 (905) 570-5103
  • Websitehttps://www.antibethera.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.